Objective: Diabetes mellitus (DM) is one of the risks linked with susceptibility of thrombosis.
We tried to inspect the effect of a novel oral antidiabetic agent, vildagliptin, in preventing …

Introduction: Type 2 diabetes mellitus (T2DM) is intricately allied with an increased risk of
atherothrombotic disease. Thrombosis is the cause of mortality in 80% of patients with …

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …

Background Diabetic patients present with an accelerated atherosclerotic process and an
increased risk for future cardiovascular events. In addition to the risk imposed by the disease …

Blood pressure and lipid profile are important determinants of cardiovascular risk in patients
with type 2 diabetes mellitus (T2DM). To identify the pleiotropic effects of vildagliptin other …

Abstract Background and Objective Cardiovascular diseases (CVDs) remain the most
identified cause of death in patients with diabetes mellitus (DM). This study aimed to …

Objective: Vildagliptin is a potent and selective dipeptidyl peptidase‑IV (DPP‑4) inhibitor that
improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell …

Glucagon-like peptide-1 (GLP-1), a gut hormone secreted from L cells in the intestine in
response to food intake, not only augments glucosedependent insulin secretion from …

Background: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors are
used to improve endothelial function in addition to treating type 2 diabetes (T2DM). The …

Abstract Aims/Introduction Dipeptidyl peptidase‐4 inhibitors might have pleiotropic
protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore …